Abcuro

United States
Calumet City, Illinois, United States
(617) 714-9759‬ ★

Company profile

Abcuro company profile

Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.

Business identity

Contact email
[email protected]
Phone number
(617) 714-9759‬
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Founded
2015-01-01

Headquarters

Headquarters
Calumet City, Illinois, United States
Postal code
02458
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
6
Total equity funding
$414.8M
Last funding
Series C / $200M / 2025-02-12
Last equity funding
Series C / $200M
Investors
19
Lead investors
5
Founders
1
Articles
52

Founders and investors

Founders

Stefano Gullà

Lead investors

Bain Capital Life SciencesMass General Brigham VenturesNew Enterprise AssociatesRedmile GroupSanofi Ventures

Investors

BlackRockForesite CapitalNew Enterprise AssociatesRA Capital ManagementSamsara BioCapital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.